Related Experiment Video
Updated: Jan 12, 2026
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Characterization of Patients With Type 2 Diabetes Experiencing Severe Hypoglycemia Exclusively due to Dipeptidyl
Jun-Ichirou Mori1, Koh Yamashita2, Toru Aizawa2
1Center for Medical Education, Faculty of Medicine, Shinshu University, Matsumoto, Japan.
Aim:
Hypoglycemia during dipeptidyl peptidase-4 inhibitor (DPP4i) monotherapy is rare; however, we encountered four such cases, prompting further analysis. Therefore, this study analyzed the characteristics of patients who experienced similar levels of hypoglycemia during monotherapy with other oral hypoglycemic agents or insulin.
Methods:
We screened 553 201 patients who visited the Critical Care and Emergency Center of our hospital from January 1, 2008, to December 31, 2019, and identified 148 patients with severe hypoglycemia taking an oral hypoglycemic agent or insulin. The patients were divided into three groups: Group D (N = 4, DPP4i alone), Group I (N = 104, insulin alone), and Group S (N = 40, sulfonylurea alone).
Results:
The patients in Group D (85.5 years) were significantly older than those in Group I (75.0 years) (p = 0.043), and those in Group S (81.5 years) were also significantly older than those in Group I (p < 0.0001). During blood sampling performed at the Critical Care and Emergency Center, the median glucose level was highest in Group D (53 mg/dL), followed by Groups I (33 mg/dL, p = 0.0137) and S (31 mg/dL, p = 0.0120). In the same samples, glycosylated hemoglobin A1c levels were lower in Group D (5.6%) than in Group I (7.3%, p = 0.012). The estimated glomerular filtration rate did not differ significantly between groups.
Conclusions:
DPP4is are generally low-risk hypoglycemic agents, with a high risk of hypoglycemia, particularly observed in older adults. These findings underscore the importance of vigilant monitoring and personalized treatment strategies to mitigate hypoglycemia risks in this population, thereby informing clinical practice and guiding future research.
Insights
Dipeptidyl peptidase-4 inhibitors (DPP4i) are low-risk for hypoglycemia, but older adults on DPP4i monotherapy experienced higher glucose levels and lower A1c. Vigilant monitoring is crucial for this population.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Hypoglycemia is a rare complication of dipeptidyl peptidase-4 inhibitor (DPP4i) monotherapy.
- This study investigates characteristics of patients experiencing severe hypoglycemia on DPP4i monotherapy compared to other oral hypoglycemic agents or insulin.
Purpose of the Study:
- To analyze patient characteristics associated with severe hypoglycemia during monotherapy with DPP4i, sulfonylurea, or insulin.
- To compare hypoglycemia severity and patient demographics across different glucose-lowering medication classes.
Main Methods:
- Retrospective analysis of 148 patients with severe hypoglycemia from January 2008 to December 2019.
- Patients categorized into three groups: DPP4i alone (Group D, n=4), insulin alone (Group I, n=104), and sulfonylurea alone (Group S, n=40).
Main Results:
- Group D patients were significantly older (85.5 years) than Group I (75.0 years).
- Median glucose levels were highest in Group D (53 mg/dL) compared to Group I (33 mg/dL) and Group S (31 mg/dL).
- Glycosylated hemoglobin A1c levels were lower in Group D (5.6%) than in Group I (7.3%).
Conclusions:
- DPP4 inhibitors, while generally low-risk, pose a significant hypoglycemia risk in older adults.
- Findings highlight the need for vigilant monitoring and personalized treatment strategies in elderly patients on DPP4i therapy.
- This research informs clinical practice and future studies on managing hypoglycemia in vulnerable patient populations.
More Related Videos
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
01:15Hypoglycemia and Glucagon
01:16Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:22Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:24Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
01:15Diabetes: Symptoms, Diagnosis, and Complications